Xingyun Zhu
Overview
Explore the profile of Xingyun Zhu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lin C, Zhu X, Jiao R, Cai X, Hu S, Lv F, et al.
Diabetes Obes Metab
. 2023 Feb;
25 Suppl 1:5-12.
PMID: 36811222
Aim: To assess the population attributable fractions (PAFs) for modifiable risk factors for microvascular complications of type 2 diabetes (T2D) in China. Materials And Methods: Data collected from the China...
12.
Jiao R, Lin C, Bai S, Cai X, Hu S, Lv F, et al.
Expert Opin Pharmacother
. 2023 Feb;
24(4):511-521.
PMID: 36799287
Background: To assess the influence of steady-state concentration, duration of action and molecular weight of glucagon-like peptide-1 receptor (GLP-1RA) on efficacy and gastrointestinal (GI) side effects in patients with type...
13.
Bai S, Lin C, Jiao R, Cai X, Hu S, Lv F, et al.
Eur J Intern Med
. 2023 Jan;
109:79-88.
PMID: 36628824
Importance: Disparities were found in the cardiovascular and renal outcomes among different glucagon-like peptide 1 receptor agonist (GLP-1RA) subtypes. However, whether the characteristics of GLP-1RA itself are associated with these...
14.
Ma Y, Lin C, Cai X, Hu S, Zhu X, Lv F, et al.
Acta Diabetol
. 2023 Jan;
60(3):435-445.
PMID: 36609865
Aims: To elucidate the association between baseline renal characteristics and the disparities in renal outcomes among patients with SGLT2i treatment. Methods: Pubmed, Medline, Embase, the Cochrane Central Register of Controlled...
15.
Hu S, Lin C, Cai X, Zhu X, Lv F, Yang W, et al.
Front Pharmacol
. 2022 Dec;
13:1018720.
PMID: 36483741
The pleiotropic efficacy of SGLT2is in patients with different eGFR levels has not been well-understood. This systematic review and meta-analysis assessed the disparities in the efficacy and safety of SGLT2i...
16.
Yang W, Cai X, Lin C, Lv F, Zhu X, Han X, et al.
Medicine (Baltimore)
. 2022 Sep;
101(37):e30563.
PMID: 36123891
Background: To evaluate the reductions of C-reactive protein (CRP) and low-density lipoprotein cholesterol (LDL-C) in different lipid-lowering drugs, and to assess the relationships between the reductions of CRP, LDL-C, and...
17.
Li Z, Lin C, Zhou J, Cai X, Zhu X, Hu S, et al.
Expert Opin Investig Drugs
. 2022 Aug;
31(9):957-964.
PMID: 35968648
Objective: To evaluate the association between dipeptidyl peptidase 4 inhibitor (DPP-4i) and the incidence of neoplasm in patients with type 2 diabetes (T2D). Methods: Pubmed, Medline, Embase, the Cochrane Central...
18.
Ma Y, Lin C, Cai X, Hu S, Zhu X, Lv F, et al.
Expert Rev Clin Pharmacol
. 2022 Jul;
15(7):877-886.
PMID: 35839519
Objective: To assess the association between the use of sodium-glucose cotransporter 2 inhibitor (SGLT2i) and the incidence of diabetic retinopathy (DR). Research Design And Methods: PubMed, Medline, Embase, the Cochrane...
19.
Lv F, Hu S, Lin C, Cai X, Zhu X, Ji L
Pharmacol Res
. 2022 Jun;
181:106278.
PMID: 35644324
Objectives: To investigate the effect of biologic therapy on risk of fracture in selected rheumatic and autoimmune diseases. Methods: The PubMed, Cochrane library, and EMBASE databases were systematically searched from...
20.
Yang W, Lin C, Zhang M, Lv F, Zhu X, Han X, et al.
Endocrine
. 2022 May;
77(2):205-212.
PMID: 35637405
Purpose: Current knowledge about the ovarian reserve in patients with type 1 diabetes is inconsistent and based on studies with small sample size. This meta-analysis aimed to produce a comprehensive...